Kastritis E, Kyrtsonis M-C, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica [Internet]. 2015Oct.31 [cited 2026Nov.3];100(11):e446-e449. Available from: https://haematologica.org/article/view/7566